First People's Hospital

Linperlisib in combination with obinutuzumab (GAZYVA) is a Phase 2 investigational program for lymphoma sponsored by The First People's Hospital of Lianyungang. Obinutuzumab is an approved anti-CD20 monoclonal antibody marketed globally; linperlisib is a small-molecule PI3K inhibitor being evaluated as a combination partner. The program is currently active with the latest milestone recorded on 19 September 2024. The combination strategy leverages obinutuzumab's established immunomodulatory mechanism with linperlisib's targeted small-molecule activity to address lymphoma pathology. Obinutuzumab holds regulatory approval in Australia (TGA, first listed August 2015), the European Union (EMA, authorised March 2026), and the United States (FDA, BLA 125486). The program is registered under NCT06592170 and represents a clinical development approach combining an established monoclonal antibody with an investigational small-molecule agent. No mechanism of action, specific target, or lead investigator information has been disclosed for linperlisib. Peak sales projections, consensus positioning, and expected next milestones remain undisclosed. The combination approach reflects contemporary lymphoma treatment strategies incorporating both immunotherapy and targeted kinase inhibition.

Lymphoma remains a significant oncology indication with diverse molecular subtypes and variable treatment responses. The combination of obinutuzumab, an established anti-CD20 agent with proven clinical benefit, with linperlisib addresses potential therapeutic gaps in lymphoma management. Obinutuzumab is already approved across major markets (US, EU, Australia), indicating established clinical utility and regulatory precedent. The addition of a PI3K inhibitor may enhance efficacy through dual pathway targeting, potentially addressing resistance mechanisms or improving outcomes in specific lymphoma subtypes. The competitive landscape includes multiple approved agents (IMBRUVICA, AFINITOR, KYPROLIS, VYXEOS LIPOSOMAL) targeting hematologic malignancies, indicating robust market activity and clinical demand. The Phase 2 stage suggests the program has advanced beyond initial safety assessment and is evaluating efficacy signals. The Chinese sponsorship by The First People's Hospital of Lianyungang indicates development within a major pharmaceutical market with significant lymphoma patient populations. Commercial significance depends on efficacy data, safety profile, and differentiation from existing combination regimens. The program's active status as of September 2024 suggests ongoing patient enrollment and data generation, with future catalysts likely including Phase 2 efficacy readouts and potential advancement decisions.

Obinutuzumab (GAZYVA): Approved anti-CD20 monoclonal antibody, administered by injection, classified as antineoplastic and immunomodulating agent (ATC L01). First approved in Australia August 2015 (TGA), with subsequent approvals in EU (March 2026) and US (FDA BLA 125486). Manufactured by Roche (Roche Products Pty Ltd, Roche Registration GmbH, Genentech). Mechanism of action and specific target information not disclosed in available facts.

Linperlisib: Small-molecule modality in combination development. Mechanism of action, molecular target, and route of administration not yet disclosed. Phase 2 development stage indicates advancement beyond initial safety evaluation.

• Combination rationale: Dual-agent approach combining established monoclonal antibody immunotherapy with investigational small-molecule targeted therapy
• Therapeutic class: Antineoplastic agents
• Related therapies in competitive space: IMBRUVICA (Janssen-Cilag), AFINITOR (Novartis), KYPROLIS (Amgen), VYXEOS LIPOSOMAL (Jazz Pharmaceuticals)
• Patent status: Not yet disclosed

Obinutuzumab (GAZYVA) Regulatory Status:

• Australia (TGA): Approved; first listed 1 August 2015; PBS codes assigned (10407R, 10418H, 11455X, 11456Y, 11457B, 11458C, 11460E, 11462G, 11468N, 11473W); sponsor Roche Products Pty Ltd
• European Union (EMA): Approved; authorisation date 5 March 2026; MAH Roche Registration GmbH; EMEA/H/C/002799
• United States (FDA): Approved; BLA 125486; sponsor Genentech
• China (NMPA): Clinical trials status; NCT05846750 registered

Linperlisib Combination Program: Regulatory status not yet disclosed. Program registered as NCT06592170 under Phase 2 development. Sponsor The First People's Hospital of Lianyungang. Expected loss of exclusivity date for linperlisib not disclosed. Pivotal trial NCT IDs not yet disclosed.

Strategic Implications: The program represents a combination therapy approach in lymphoma, leveraging an established approved agent (obinutuzumab) with an investigational small-molecule partner (linperlisib). Sponsorship by a Chinese hospital-based research institution indicates development focus within the Asian market, particularly China. Phase 2 status as of September 2024 suggests active enrollment and efficacy evaluation, with future catalysts including interim or final Phase 2 data readouts.

Competitive Implications: The combination strategy positions against both monotherapy standards and emerging dual-agent approaches. Obinutuzumab's established regulatory approval and clinical utility provide a validated backbone, reducing development risk compared to novel monotherapy combinations. Competitive differentiation will depend on Phase 2 efficacy signals, safety profile, and patient population specificity relative to approved alternatives (IMBRUVICA, AFINITOR, KYPROLIS).

Future Catalysts: Phase 2 efficacy and safety data readouts; potential advancement to Phase 3 based on interim analysis; regulatory feedback from NMPA (China) or other authorities; publication of clinical results; potential partnership or licensing discussions; expansion to additional lymphoma subtypes or patient populations.

Development Trajectory: Active Phase 2 status indicates program advancement beyond initial safety evaluation. Undisclosed mechanism of action and target for linperlisib suggest proprietary development. Expected next milestone timing and label not yet disclosed, limiting visibility into near-term catalysts.